A5102985539- Chronic Obstructive Pulmonary Disease (COPD) Research
- Inhalation and Respiratory Drug Delivery
- Asthma and respiratory diseases
- Respiratory Support and Mechanisms
- Pharmaceutical Practices and Patient Outcomes
- Pediatric Hepatobiliary Diseases and Treatments
- Gallbladder and Bile Duct Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Opioid Use Disorder Treatment
- Heart Failure Treatment and Management
- Cardiac pacing and defibrillation studies
- Uterine Myomas and Treatments
- Medication Adherence and Compliance
- Biliary and Gastrointestinal Fistulas
- Pharmacological Effects and Toxicity Studies
- Poisoning and overdose treatments
- Gastrointestinal disorders and treatments
- Sleep and related disorders
- Analytical Methods in Pharmaceuticals
- Obstructive Sleep Apnea Research
- AI in Service Interactions
- Sleep and Work-Related Fatigue
- Delphi Technique in Research
- Pharmaceutical industry and healthcare
- Sexual Differentiation and Disorders
B.J. Medical College
2025
Pacific Medical (China)
2025
Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College
2021-2023
Nutrasource
2023
Sibley Memorial Hospital
2021
Montefiore Medical Center
2016
Purdue Pharma (Canada)
2013-2014
Purdue Pharma (United States)
2013-2014
Health Economics and Outcomes Research (United Kingdom)
2013
Brown University
2011
Choledocholithiasis, a condition characterized by stones in the common bile duct (CBD), frequently results obstructive jaundice and associated complications. Endoscopic retrograde cholangiopancreatography (ERCP) has emerged as gold standard for treating this condition, offering minimally invasive therapeutic approach. However, while ERCP is widely used, its efficacy managing diverse clinical presentations potential complications necessitates further investigation. Additionally, data on...
Background:We assessed the cost-effectiveness of single-inhaler fluticasone furoate (FF)/ umeclidinium (UMEC)/vilanterol (VI) versus FF/VI or UMEC/VI from a Canadian public healthcare perspective, incorporating data IMPACT trial in chronic obstructive pulmonary disease (COPD) (NCT02164513).Methods: Baseline inputs and treatment effects were populated into validated GALAXY-COPD progression model.Canadian unit costs drug (Canadian dollars [C$], 2017) applied to resource utilization...
Background: The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcomes Results (LEADER) clinical trial demonstrated that liraglutide added to standard-of-care (SoC) therapy for type 2 diabetes (T2D) with established cardiovascular disease (CVD) or elevated (CV) risk was associated lower rates death from CVD, nonfatal myocardial infarction (MI), stroke than SoC alone. Objective: objective this study assess the cost-effectiveness (CE) budget impact vs T2D patients CVD...
Purpose: The 24-week INTREPID trial demonstrated the clinical benefits of once-daily single-inhaler triple therapy (SITT) with fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) versus non-ELLIPTA multiple-inhaler (MITT) in patients symptomatic chronic obstructive pulmonary disease (COPD). This analysis assessed cost-effectiveness FF/UMEC/VI MITT for treatment COPD from a United Kingdom (UK) National Health Service (NHS) perspective. Patients Methods: was conducted using...
Chronic obstructive pulmonary disease is associated with a high healthcare resource and cost burden. Healthcare utilization was analyzed in patients symptomatic chronic at risk of exacerbations the FULFIL study. Patients received either once-daily, single inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol) 100 µg/62.5 µg/25 µg or twice-daily dual inhaled corticosteroid/long-acting beta agonist (budesonide/formoterol) 400 µg/12 µg. phase III, randomized, double-blind,...
The rheumatologic manifestations of human immunodeficiency virus (HIV) infection have been recognized since the early days epidemic and are characteristic this disorder. It has noted that clinical spectrum rheumatic disorders in patients with HIV changed advent highly active antiretroviral therapy (HAART) mid-1990s. Furthermore, may become clinically apparent disease during or after they treated immunosuppressive therapy. emergence develop such be confused known to associated underlying...
Aims: Heart failure with reduced ejection fraction (HFrEF) has a substantial impact on costs and patients' quality-of-life. This study aimed to estimate the cost-effectiveness of implantable cardioverter defibrillators (ICD), cardiac resynchronization therapy pacemakers (CRT-P), (CRT-D), optimal pharmacologic (OPT) in patients HFrEF, from US payer perspective.Materials methods: The analyses were conducted by adapting UK-based (CEA) perspective incorporating real world evidence (RWE) baseline...
For patients with chronic obstructive pulmonary disease (COPD) who remain symptomatic despite maintenance treatment, clinical management guidelines recommend a stepwise escalation from monotherapy to dual therapy, and therapy triple therapy. However, in practice, are often escalated directly based on severity. This study evaluated the cost-effectiveness of once-daily, single-inhaler fluticasone furoate, umeclidinium, vilanterol (FF/UMEC/VI) compared long-acting muscarinic antagonist...
The clinical benefit of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus twice-daily budesonide/formoterol (BUD/FOR) for patients with symptomatic chronic obstructive pulmonary disease (COPD) was demonstrated in a trial setting (FULFIL [NCT02345161]). lifetime cost-effectiveness analysis FF/UMEC/VI BUD/FOR, based on FULFIL data, is reported here. A previously developed and validated GALAXY-COPD linked-risk equation model used to assess the from UK National Health...
Middle-of-the-night (MOTN) awakenings with difficulty returning to sleep are among the most common symptoms of insomnia. Despite epidemiological studies that have been conducted, there is a lack data on impact MOTN health status and socioeconomic indicators in comparison other insomnia symptoms.Data were analyzed from 2011 US National Health Wellness Survey (adults ≥18 years old; N=60,783), which asked respondents whether they had experienced specific (ie, awakenings, falling asleep, waking...
The IMPACT trial demonstrated superior outcomes following 52 weeks of once-daily single-inhaler treatment with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) (100/62.5/25 μg) compared FF/VI (100/25 or UMEC/VI (62.5/25 μg). This study evaluated the cost-effectiveness FF/UMEC/VI for chronic obstructive pulmonary disease (COPD) from a UK National Health Service perspective.Patient characteristics and effects were populated into hybrid decision tree/Markov economic model. Costs...
To evaluate the impact of increased access restrictions to branded oxycodone hydrochloride extended-release tablets (oxycodone HCl ER), on healthcare utilization and costs in patients using long-acting opioids (ER/LA opioids) from health plan perspective during period 1/1/2009 6/30/2012.This retrospective cohort study analyzed claims data for adult US plans that ER restrictions. Study groups were segmented into commercial Medicare payers, by prior authorization (PA) tier change (TC)...
Abstract Background Cost-effectiveness of once-daily umeclidinium bromide (UMEC) was compared with tiotropium (TIO) and glycopyrronium (GLY) in patients chronic obstructive pulmonary disease (COPD) from a UK National Health Service (NHS) perspective. Methods A linked-equation model implemented to estimate COPD progression, associated healthcare costs, exacerbations rates, life years (LY) quality-adjusted LY (QALYs). Statistical risk equations for endpoints resource use were derived the...
Oesophageal duplication is a rare congenital malformation which occurs due to embryogenesis errors. It accounts for 15% of all digestive tract duplications, most common being ileal duplications. Here we report case tubular and novel surgical approach its management. 6 year male child, 11 kgs, presented with progressive dysphagia solids > liquids since birth. He had stunted growth, height weight were less than 50th percentile. On investigations, Barium swallow CECT neck thorax was done...
<b>Introduction:</b> Once-daily UMEC/VI 62.5/25µg was compared to twice-daily GLY/FOR 18/9.6µg in the AERISTO trial, a phase IIIb randomized, double-blind, 24-week study (Maltais F. et al, Adv Ther 2019;36[9]). <b>Aim and Objectives:</b> To assess cost-effectiveness of vs for treatment symptomatic patients with COPD from UK National Healthcare System perspective using data. <b>Methods:</b> Analysis conducted validated model implemented linked risk-equation approach (GALAXY; Briggs A.H. Med...